Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy

Journal of Urology

Volumn 166, Issue 3, 2001, Pages 882-886

  Goluboff, Erik T ^a   Prager, Diane ^b   Rukstalis, Daniel ^b   Giantonio, Bruce ^b   Madorsky, Martin ^b   Barken, Israel ^b   Weinstein, I Bernard ^b   Partin, Alan W ^b   Olsson, Carl A ^b   Holden, Stuart ^b   Brosman, Stanley ^b   Shapiro, Richard ^b   Tchekmedyian, Simon ^b   Gottlieb, Chester ^b   Himsl, Kyle ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NONE

Author keywords

Apoptosis; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PLACEBO; PROSTATE SPECIFIC ANTIGEN; SULINDAC SULFONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0034889252     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65856-9     Document Type: Article

References (21)

1. Cancer statistics, 2000
2. Prostate specific antigen: A decade of discovery-what we have learned and where we are going
3. Evaluation and management of men whose radical prostatectomies failed: Results of an international survey
4. Treatment with finasteride following radical prostatectomy for prostate cancer
5. Natural history of progression after PSA elevation following radical prostatectomy
6. Carcinoma of the prostate
7. Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
8. Selective apoptosis of neoplastic cells accompanies polyp regression in familial adenomatous polyposis (FAP) patients treated with FGN-1 (sulindac sulfone): Evidence for a cyclooxygenase independent mechanism
9. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
10. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
11. Growth inhibitory activity of FGN-1 and analogues in 13 human tumor lines of various histogenesis
12. Exisulind induction of apoptosis involves guanosine 3′, 5′-monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin
13. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
14. Exisulind induced apoptosis in prostate cancer cells is associated with down-regulation of androgen responsive elements
15. Exisulind prevents adenoma formation in familial adenomatous polyposis (FAP)
16. Exisulind continues to prevent colonic adenoma formation in familial adenomatous polyposis (FAP) patients treated for 18 months
17. Apoptosis in human prostate cancer cells shows enhanced sensitivity to taxol in the presence of exisulind
18. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone)
19. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
20. Inhibition of urinary bladder tumorigenesis in rats by exisulind (Aptosyn)
21. Sulindac and its sulfone derivative inhibit colon cancer via modification of intestinal bile acids